Le Lézard
Classified in: Health
Subjects: LAW, BFA, PLW

Statement by ResMed on Plans to Renew Its Patent Infringement Case Against Fisher & Paykel


SAN DIEGO, May 17, 2017 /PRNewswire/ -- ResMed today issued the following statement from David Pendarvis, the company's global general counsel and chief administrative officer:

Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/74629527-resmed-patent-infringement-case-against-fisher-paykel/

"ResMed filed a motion to dismiss the current International Trade Commission (ITC) complaint so that we can refile and incorporate additional evidence generated since the original complaint was filed. We believe this will make our strong case even stronger, and we remain confident in our position in the ITC. ResMed's innovations have transformed the treatment of sleep-disordered breathing. We're committed to protecting our innovation, which is why we've engaged in global legal proceedings with Fisher & Paykel."

About ResMed
ResMed (NYSE: RMD) changes lives with award-winning medical devices and cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 3 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company ? improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.­­ ResMed.com | Facebook | Twitter | LinkedIn

For media:

For investors:

Alison Graves

Agnes Lee

858-836-6789

858-836-5971

[email protected]

[email protected]

 

ResMed Inc. logo.

 

SOURCE ResMed


These press releases may also interest you

at 15:30
Magic Mushroom Delivery Thrives Amidst TikTok Ban Challenges
The Magic Mushroom Delivery, a prominent leader in the magic mushroom industry, has seen significant growth in recent year, expanding its services to offer both same-day delivery in California and fast nationwide shipping. Based in Oakland,...

at 15:30
EPA, FDA, and USDA Issue Joint Regulatory Plan for Biotechnology
In response to President Biden's Executive Order 14081, "Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy," the U.S. Environmental Protection Agency (EPA), the U.S. Food and Drug...

at 15:30
From Pioneers to Leaders: Thought Technology Ltd Celebrates its 50th Anniversary at AAPB Conference
Thought Technology Ltd., a well-established name in the biofeedback equipment sector, is delighted to announce its 50th anniversary. Since its inception, the company has been at the...

at 15:28
NEW JERSEY MARINE BECOMES PROCURE'S 7,000TH PATIENT TO COMPLETE CANCER TREATMENT
Retired New Jersey Marine Robert Hanley became the 7,000th patient to complete treatment at ProCure Proton Therapy Center, surpassing a major milestone at the tri-state region's original proton therapy facility. Hanley was diagnosed with lung cancer...

at 15:20
ArkeaBiotm Raises $26.5M to Reduce Greenhouse Gas Emissions with Methane Vaccine
ArkeaBiotm, a leading ag-biotech start-up developing a vaccine to reduce livestock methane emissions, today announced the close of a $26.5 million Series A financing round. The raise was led by current investor Breakthrough Energy Ventures (BEV), and...

at 14:55
The US Laboratory Developed Tests (LDTs) Market to Contribute $3.08 Billion Revenue Share by 2029 - Personalized Medicines Boosting the Market Opportunities - Exclusive Focus Insight Report by Arizton
According to Arizton's latest focus insight report, the US laboratory developed tests market is growing at a CAGR of 3.40% from 2023 to 2029....

More news about Health...


News published on and distributed by: